CoreAge Rx vs Mevo Health
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Mevo Health head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 63 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make Mevo Health a bad call — it's best for readers considering provider-reviewed injection care who obtain the exact term, medication supply and patient payment agreement first. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | Mevo Health |
|---|---|---|
| Brief Score | 94/100 (A) | 63/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | Advertised injection from $199/month Current homepage names compounded injections; full selected term, payment and supplied quantity unconfirmed. Confirm the patient agreement and refund cutoff. A projected oral-results graphic does not establish an oral medication offer. Full price detailsCompounded semaglutide injections advertised; complete selected-plan quote unknown; current homepage starts at $199/month without a full selected commitment or supplied quantity |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | Advertised injection from $259/month Monthly, quarterly and six-month choices described; full longer-plan charge and selected supply unconfirmed. Monthly shipment and provider access advertised. Cancellation before next billing cycle described; precise advance deadline and unused-prepaid refund calculation unconfirmed. Full price detailsCompounded tirzepatide injections advertised; complete selected-plan quote unknown; current treatment page starts at $259/month with monthly, quarterly and six-month choices but no full selected longer-term payment |
| Coverage | US only; restrictions by state, confirmed at intake | Available only in U.S. states where the service and treating clinician operate; complete treatment-state list unconfirmed |
| Brand-name access | Not confirmed | Brand ingredient comparisons do not establish a named branded GLP-1 prescribing service. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
Mevo Health: Advertised injection starts at $199/$259 monthly. Full selected payment, supply and refund agreement remain unconfirmed; an oral-results projection is not a verified product offer.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.